Autolus Therapeutics (AUTL) Cost of Revenue (2024 - 2025)

Autolus Therapeutics (AUTL) posted quarterly Cost of Revenue of $25.3 million for Q4 2025, up 122.45% year-on-year from $11.4 million in Q4 2024, and down 11.57% on a QoQ basis from $28.6 million in Q3 2025.

Autolus Therapeutics (AUTL) Cost of Revenue (2024 - 2025) Analysis & Trends

Autolus Therapeutics (AUTL) has reported Cost of Revenue for 2 consecutive years, with $25.3 million the latest figure, recorded in Q4 2025.

  • Quarterly Cost of Revenue rose 122.45% year-over-year to $25.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $96.4 million (up 746.31% YoY) and the FY2025 annual result came in at $96.4 million, up 746.31% from the prior year.
  • Cost of Revenue declined to $25.3 million in Q4 2025 per AUTL's latest filing, from $28.6 million in the prior quarter.
  • Over the last five years, Cost of Revenue for AUTL reached as high as $28.6 million in Q3 2025 and fell as low as $11.4 million in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 167.22 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 392.80 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 296.00 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 145.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Autolus Therapeutics 393.78 Mn 93.07 Mn -1.04 Mn 25.33 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 25.33 Mn
Dec 31, 2025 25.33 Mn
Sep 30, 2025 28.64 Mn
Sep 30, 2025 28.64 Mn
Jun 30, 2025 24.45 Mn
Jun 30, 2025 24.45 Mn
Mar 31, 2025 17.95 Mn
Mar 31, 2025 17.95 Mn
Dec 31, 2024 11.39 Mn
Dec 31, 2024 11.39 Mn